Immunology News and Research

Latest Immunology News and Research

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

11 Feb 2010

PAREXEL International, Proteome Sciences form biomarker alliance

PAREXEL International Corporation, a leading global biopharmaceutical services provider, and Proteome Sciences plc, a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of an alliance focused on enhancing PAREXEL's biomarker capabilities for early phase clinical development. PAREXEL is using Proteome Sciences' PS Biomarker Services™ protein and peptide biomarker capabilities to support biopharmaceutical companies in making earlier assessments of new compounds in development.

From Parexel 11 Feb 2010

Eczema in early childhood may influence behavior and mental health later in life

Eczema in early childhood may influence behavior and mental health later in life. This is a key finding of a prospective birth cohort study to which scientists of Helmholtz Zentrum München contributed.

11 Feb 2010

Eczema can lead to behavioral and psychological problems in children

11 Feb 2010

Researchers study new ways to block movement of cells that cause autoimmune diseases and cancer

University of Adelaide researchers in Australia are finding new ways to block the movement of cells in the body which can cause autoimmune diseases and the spread of cancer.

10 Feb 2010

YM BioSciences receives additional AeroLEF patents in U.S.

YM BioSciences Inc., announced that it has been granted two additional patents in the US for AeroLEF(R), the Company's proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe acute pain. US patent numbers 7,648,981 and 7,648,982 extend the life of YM's AeroLEF patent estate in the US to 2024.

10 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

New research suggests closantel drug may be useful in combating river blindness

Scientists at The Scripps Research Institute have discovered a potential new use for the drug closantel, currently the standard treatment for sheep and cattle infected with liver fluke. The new research suggests that the drug may be useful in combating river blindness, a tropical disease that is the world's second leading infectious cause of blindness for humans.

10 Feb 2010

VSV has potential to be genetically modified to serve as anti-cancer agent

Vesicular stomatitis virus, or VSV, has long been a model system for studying and understanding the life cycle of negative-strand RNA viruses, which include viruses that cause influenza, measles and rabies.

10 Feb 2010

Study of complement reaction can help eliminate reperfusion injuries

Researchers have teased out the molecular process that can shut down a marauding, often deadly immune response that kills thousands each year who suffer battlefield casualties, heart attacks, strokes, automobile accidents and oxygen deprivation, according to an article published in the January edition of Molecular Immunology.

10 Feb 2010

GA²LEN and EAACI warn: Older antihistamines in OTC allergy medications may be hazardous

A joint GA²LEN /EAACI report to be published in "Allergy" and available online on 8 February reviews new data on the treatment of allergies with older antihistamines compared with newer, second-generation H1-antihistamines. The research was funded by GA²LEN, an EU-funded Network of Excellence.

10 Feb 2010

Loyola University Chicago offers new research-intensive program for healthcare industry

Registration is underway for Loyola University Chicago's new infectious disease & immunology master's degree program that will prepare graduates for challenging health-related positions in government, research and private industry.

10 Feb 2010

NIAID awards Tulane University over $15M to develop Lassa fever vaccine and treatment

The National Institute of Allergies and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a five-year contract totaling $15,254,919 to Tulane University for its ongoing efforts to treat and prevent Lassa fever, an often deadly viral disease that threatens hundreds of thousands of people annually in West Africa and is classified as a potential bioterrorism threat.

10 Feb 2010

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and Tulane University, today announced a major extension of the collaborative effort to combat viral hemorrhagic fever (VHF), an effort that will generate an additional $800,000 in contract revenue for Corgenix over the life of the contract.

9 Feb 2010

Plant-produced antibodies can help prevent infection

The first head-to-head comparison of therapeutic monoclonal antibodies produced from plants versus the same antibodies produced from mammalian cells has shown that plant-produced antibodies can fight infection equally well.

9 Feb 2010

GIS: Tbx3 gene improves quality of stem cells reprogrammed from differentiated cells

In the 7 Feb. 2010 issue of the journal Nature, scientists at the Genome Institute of Singapore (GIS), report that a genetic molecule, called Tbx3, which is crucial for many aspects of early developmental processes in mammals, significantly improves the quality of stem cells that have been reprogrammed from differentiated cells.

7 Feb 2010

FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficiency

Talecris Biotherapeutics, Inc. announced today that it was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, especially emphysema, which typically emerges in the fourth decade of life. Currently, there are no approved, inhaled treatments available for the treatment of AAT deficiency.

5 Feb 2010

Research could help in developing protein-based vaccine against maternal malaria

Researchers at the University of Copenhagen have become the first in the world to synthesize the entire protein that is responsible for life-threatening malaria in pregnant women and their unborn children.

5 Feb 2010

Merck announces $1.5M funding commitment over three years to BC Centre for Excellence in HIV/AIDS

Today, Merck is pleased to announce its $1.5 million funding commitment over three years to the BC Centre for Excellence in HIV/AIDS (BC-CfE) in support of its research program entitled "Seek and Treat for Optimal Prevention of HIV/AIDS", known as the "seek & treat" program, which will expand HIV treatment and care for hard-to-reach residents in Prince George and Vancouver's Downtown Eastside.

5 Feb 2010

Mapping of human genome modification during embryonic development

Scientists at The Genome Institute of Singapore (GIS) and The Scripps Research Institute (TSRI) led an international effort to build a map that shows in detail how the human genome is modified during embryonic development.

4 Feb 2010

Immunology News and Research

Latest Immunology News and Research

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

PAREXEL International, Proteome Sciences form biomarker alliance

Eczema in early childhood may influence behavior and mental health later in life

Eczema can lead to behavioral and psychological problems in children

Researchers study new ways to block movement of cells that cause autoimmune diseases and cancer

YM BioSciences receives additional AeroLEF patents in U.S.

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

New research suggests closantel drug may be useful in combating river blindness

VSV has potential to be genetically modified to serve as anti-cancer agent

Study of complement reaction can help eliminate reperfusion injuries

GA²LEN and EAACI warn: Older antihistamines in OTC allergy medications may be hazardous

Loyola University Chicago offers new research-intensive program for healthcare industry

NIAID awards Tulane University over $15M to develop Lassa fever vaccine and treatment

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Plant-produced antibodies can help prevent infection

GIS: Tbx3 gene improves quality of stem cells reprogrammed from differentiated cells

FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficiency

Research could help in developing protein-based vaccine against maternal malaria

Merck announces $1.5M funding commitment over three years to BC Centre for Excellence in HIV/AIDS

Mapping of human genome modification during embryonic development

Immunology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut